K-numberK233337
Device nameFreespira Breathing System
ApplicantFreespira, Inc.
Product codeSEN
Device classClass II
Decision dateApr 24, 2025
DecisionSubstantially Equivalent
Regulation882.5050
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

Freespira is a biofeedback device that guides users through monitored breathing exercises to reduce stress. It measures exhaled carbon dioxide (EtCO2) levels and respiration rate via a sensor connected to a mobile app. For adults, it is indicated as adjunctive treatment for panic disorder and posttraumatic stress disorder; for adolescents aged 13-17, it treats stress and anxiety symptoms. The device requires healthcare provider direction and is used alongside other pharmacological or non-pharmacological interventions.

Technological characteristics

The subject device has identical design, dimensions, and materials as the predicate device (K180173). It maintains the same technological characteristics, including the sensor and mobile app for real-time biofeedback on EtCO2 and respiration rate. The fundamental difference is expanded labeling to include use in adolescents aged 13-17 for stress and anxiety disorders, whereas the predicate was limited to adults with panic disorder and PTSD.

Test standards cited

Biocompatibility testing per ISO 10993-1:2009(R)2013; electromagnetic compatibility and electrical safety per IEC 60601-1:1988+A1:1991+A2:1995, ANSI/AAMI ES60601-1:2005, IEC/EN 60601-1-2:2007, IEC 60601-1-4:1996+A1:1999, and IEC 60601-1-11:2010; software verification per FDA guidance on software in medical devices.

Substantial equivalence argument

Freespira is substantially equivalent because it has identical design, materials, and technological characteristics to the predicate K180173. Clinical data from feasibility studies, a randomized controlled trial in adolescents, and real-world evidence from 106 adolescents treated during COVID-19 demonstrate safety and effectiveness comparable to adults in the same treatment period. The expanded indication to adolescents aged 13-17 raised no new safety concerns—adverse events were similar to adult studies and the single rare event (facial numbness) resolved immediately upon stopping the exercise. Protocol adherence and symptom reduction rates in adolescents were equivalent to older age groups, supporting that the device performs as safely and effectively in this new population as in the predicate population.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →